We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.
Features Partner Sites Information LinkXpress
Sign In
Advertise with Us


31 Oct 2018 - 02 Nov 2018
03 Nov 2018 - 07 Nov 2018

Anticancer Compounds Found in Medicinal Plant

By BiotechDaily International staff writers
Posted on 11 Oct 2017
Print article
Image: Ambrosia arborescens, the source of compounds toxic to cancer stem cells, is a medicinal plant with analgesic, anti-inflammatory, and antiseptic properties (Photo courtesy of Wikimedia Commons).
Image: Ambrosia arborescens, the source of compounds toxic to cancer stem cells, is a medicinal plant with analgesic, anti-inflammatory, and antiseptic properties (Photo courtesy of Wikimedia Commons).
Compounds isolated from the medicinal plant Ambrosia arborescens or derived from them synthetically were found to have potent toxic effect on cancer stem cells in three different breast cancer cell lines.

Investigators at Lund University (Sweden) examined the anti-cancer activity of sesquiterpene lactones (SLs) isolated from A. arborescens and of synthetic derivatives in breast cancer cell lines, with a specific focus on activity against cancer stem cells (CSCs). Sesquiterpene lactones are a class of chemical compounds comprising three isoprene units and containing a lactone ring. They are found in many plants and can cause allergic reactions and toxicity if overdosed.

For the current study, the breast cancer cell lines MCF-7, JIMT-1, and HCC1937 and the normal-like breast epithelial cell line MCF-10A were treated with the SLs damsin and coronopilin, isolated from A. arborescens, and with ambrosin and dindol-01, synthesized using damsin.

Doses of the compounds in the micromolar range were used for investigating effects on cell proliferation, cell cycle phase distribution, cell death, micronuclei formation, and cell migration. Western blot analysis was used to investigate proteins involved in cell cycle regulation as well as in the NF-kappaB pathway, since SLs have been shown to inhibit this transcription factor. Specific CSC effects were investigated using three different CSC assays.

Results published in the September 1, 2017, online edition of the journal PLOS One revealed that that all compounds inhibited tumor necrosis factor-alpha (TNF-alpha)-induced translocation of NF-kappaB to the cell nucleus. Dose response assays showed that all compounds were cytotoxic to the breast cancer cell lines (MCF-7, JIMT-1, and HCC1937) as well as to the MCF-10A normal-like breast epithelial cell line; however, the latter cell line was least affected. Damsin and ambrosin treatment increased the number of micronuclei, and another sign of DNA damage was the increased level of p53. The most toxic compound was ambrosin, which was also found to reduce the CSC subpopulation of the JIMT-1 cell line.

"Both the natural and the synthetic substances inhibit the growth and spread of cancer stem cells in breast cancer cell lines. This is the first time that it has been successfully proven by research", said senior author Dr. Stina Oredsson, professor of biology at Lund University. "Different cancer cells have different abilities to survive chemotherapy. Cancer stem cells can be considered the most dangerous type of cancer cells, as they appear to have an inherent resistance to the chemotherapeutic drugs used today. Our results can contribute to the development of new drugs against cancer stem cells but, unfortunately, it takes a long time to get from basic research to usable drugs."

Related Links:
Lund University

Print article



view channel

Collaborative Agreement to Aid in Setting Guidelines for Evaluating Potential Ebola Therapy

Cooperation between an Israeli biopharmaceutical company and medical branches of the US government is designed to set ground rules for continued evaluation of an experimental therapy for Ebola virus disease. RedHill Biopharma Ltd. (Tel Aviv, Israel), a biopharmaceutical company primarily focused on development and c... Read more
Copyright © 2000-2018 Globetech Media. All rights reserved.